300199 翰宇药业
已收盘 12-31 15:00:00
资讯
新帖
简况
股市必读：翰宇药业（300199）12月29日董秘有最新回复
证券之星 · 12-30 01:19
股市必读：翰宇药业（300199）12月29日董秘有最新回复
翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成
证券之星 · 12-29 20:51
翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成
翰宇药业：海南昊天健康科技有限公司已无关联关系
证券之星 · 2025-12-25
翰宇药业：海南昊天健康科技有限公司已无关联关系
翰宇药业战略参股碳云智肽
新京报 · 2025-12-22
翰宇药业战略参股碳云智肽
翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%
证券之星 · 2025-12-18
翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%
翰宇药业：国际业务保持良好增长势头
证券之星 · 2025-12-16
翰宇药业：国际业务保持良好增长势头
翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%
证券之星 · 2025-12-11
翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%
翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%
证券之星 · 2025-12-08
翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%
翰宇药业：多肽原料药总产能可达5吨以上
证券之星 · 2025-12-03
翰宇药业：多肽原料药总产能可达5吨以上
医药“一哥”高管，空降翰宇药业
蓝鲸财经 · 2025-11-28
医药“一哥”高管，空降翰宇药业
翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%
证券之星 · 2025-11-17
翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%
翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块
证券之星 · 2025-11-13
翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块
翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%
证券之星 · 2025-11-06
翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%
翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升
证券之星 · 2025-10-31
翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升
翰宇药业：司美格鲁肽III期临床进入收尾阶段
证券之星 · 2025-10-30
翰宇药业：司美格鲁肽III期临床进入收尾阶段
翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%
证券之星 · 2025-10-21
翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%
翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押
中金财经 · 2025-09-26
翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押
翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等
证券之星 · 2025-09-25
翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等
翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本
美股速递 · 2025-09-25
翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本
股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%
证券之星 · 2025-08-25
股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":17.9,"timestamp":1767164622000,"preClose":18.25,"halted":0,"volume":20791854,"delay":0,"changeRate":-0.0192,"floatShares":746000000,"shares":883000000,"eps":-0.0765,"marketStatus":"已收盘","change":-0.35,"latestTime":"12-31 15:00:00","open":18.39,"high":18.4,"low":17.9,"amount":375000000,"amplitude":0.0274,"askPrice":17.9,"askSize":1233,"bidPrice":17.89,"bidSize":914,"shortable":0,"etf":0,"ttmEps":-0.0765,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":18.25,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":20.08,"lowLimit":16.43,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":24.83,"roa":"--","roe":"11.62%","epsLYR":-0.2,"committee":0.182669,"marketValue":15810000000,"turnoverRate":0.0279,"status":1,"floatMarketCap":13348000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2595734448","title":"股市必读：翰宇药业（300199）12月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595734448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595734448?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:19","pubTimestamp":1767028749,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，翰宇药业报收于18.59元，下跌0.75%，换手率2.64%，成交量19.69万手，成交额3.68亿元。公司司美格鲁肽减重适应症受试者已完成全部治疗访视，随访工作12月底可全部完成；司美格鲁肽降糖适应症受试者将于12月底完成治疗访视，随访工作将于 2026年1月全部结束。当日关注点来自交易信息汇总：12月29日主力资金净流出2748.44万元，散户资金净流入3006.47万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000000767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","300199","BK0077","BK0070","BK0028"],"gpt_icon":0},{"id":"2595780953","title":"翰宇药业：司美格鲁肽减重适应症随访工作12月底可全部完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595780953?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:51","pubTimestamp":1767012668,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业12月29日在投资者关系平台上答复投资者关心的问题。还有RWA还有没有后续，要给股民一个交代呀翰宇药业回复：尊敬的投资者您好！公司司美格鲁肽减重适应症受试者已完成全部治疗访视，随访工作12月底可全部完成；司美格鲁肽降糖适应症受试者将于12月底完成治疗访视，随访工作将于 2026年1月全部结束。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900034562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0070","300199","BK0077","BK0028"],"gpt_icon":0},{"id":"2594033234","title":"翰宇药业：海南昊天健康科技有限公司已无关联关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2594033234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594033234?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:52","pubTimestamp":1766667133,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，董秘，请问贵公司子公司海南昊天健康科技有限公司，是否还在正常营业运作？是归属全资子公司吗？翰宇药业回复：尊敬的投资者您好，海南昊天健康科技有限公司原系公司全资子公司，后续基于业务布局优化调整已处置，现已与公司无关联关系。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","300199","BK0239","BK0077","BK0028"],"gpt_icon":0},{"id":"2593510716","title":"翰宇药业战略参股碳云智肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510716","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593510716?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:08","pubTimestamp":1766390880,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 12月22日，据翰宇药业微信公众号消息，近日翰宇药业与深圳碳云智肽药物科技有限公司（简称“碳云智肽”）正式达成战略投资合作。根据协议约定，翰宇药业将以1000万元现金认购碳云智肽新增注册资本，增资完成后持有其0.6623%股权，标志着双方从前期研发协作迈向资本绑定与产业协同的深度合作新阶段。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/22/5667201163137721813.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/22/5667201163137721813.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1766390338129383.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1766390338129383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","BK0070","BK0028","300199","BK0077","BK0188"],"gpt_icon":0},{"id":"2592790106","title":"翰宇药业（300199）披露控股股东、实际控制人办理部分股票质押暨股票解除质押业务，12月18日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592790106","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592790106?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:07","pubTimestamp":1766066829,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，翰宇药业报收于17.91元，较前一交易日下跌0.56%，最新总市值为158.19亿元。该股当日开盘17.9元，最高18.44元，最低17.83元，成交额达3.04亿元，换手率为2.25%。公司近日发布公告称，控股股东、实际控制人曾少贵先生近日办理了部分股票质押及解除质押业务。同日，曾少贵先生解除质押股份19,000,000股，占其所持股份比例19.28%，占公司总股本比例2.15%。本次质押与解质后，曾少贵先生累计质押股份数量不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800037994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0188","BK0028","BK0070","BK0077","BK0239"],"gpt_icon":0},{"id":"2591130984","title":"翰宇药业：国际业务保持良好增长势头","url":"https://stock-news.laohu8.com/highlight/detail?id=2591130984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591130984?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:52","pubTimestamp":1765889538,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：股价喋喋不休！是什么情况？据说现在公司没有订单？是否属实翰宇药业回复：尊敬的投资者您好，2025年，公司的国际业务继续保持着良好的增长势头，海外市场业务正有序推进，我们与核心合作伙伴始终保持长期稳定的战略合作关系。公司严格按照相关法律法规履行信息披露义务，如签订达到披露标准的重大合同，公司将严格按照监管要求及时发布公告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600038122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0077","BK0070","BK0239","BK0028"],"gpt_icon":0},{"id":"2590851158","title":"翰宇药业（300199）披露控股股东、实际控制人办理部分股票解除质押暨办理股票质押业务，12月11日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590851158","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590851158?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:03","pubTimestamp":1765461836,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，翰宇药业报收于18.75元，较前一交易日下跌0.79%，最新总市值为165.61亿元。该股当日开盘19.1元，最高19.16元，最低18.75元，成交额达3.19亿元，换手率为2.26%。公司近日发布公告称，控股股东、实际控制人曾少贵、曾少彬近日办理了部分股票解除质押及新的股票质押业务。本次质押后，曾少贵累计质押47,190,000股，占其所持股份47.89%；曾少彬累计质押12,500,000股，占其所持股份57.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300199","BK0188","BK0239","BK0077","BK0028"],"gpt_icon":0},{"id":"2589133675","title":"翰宇药业（300199）公司公告补选非独立董事及修订公司章程，12月08日股价上涨1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589133675","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589133675?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:43","pubTimestamp":1765187000,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，翰宇药业报收于19.2元，较前一交易日上涨1.59%，最新总市值为169.58亿元。该股当日开盘19.02元，最高19.45元，最低19.01元，成交额达5.93亿元，换手率为4.14%。近日，深圳翰宇药业股份有限公司发布2025年第四次临时股东会决议公告，披露公司已于2025年12月5日召开2025年第四次临时股东大会，审议通过了补选第六届董事会非独立董事、修订公司章程、调整公司架构及办理工商变更登记、修订多项内部制度等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800021730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0028","BK0077","BK0188","BK0239","BK0070"],"gpt_icon":0},{"id":"2588915530","title":"翰宇药业：多肽原料药总产能可达5吨以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2588915530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588915530?lang=zh_cn&edition=full","pubTime":"2025-12-03 11:48","pubTimestamp":1764733699,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好，关于替尔泊肽原料药明年的预计产能是？谢谢翰宇药业回复：您好，目前公司多肽原料药总产能可达5吨以上，具体产品的年度排产计划将综合市场及合作需求等动态制定，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300013704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0077","BK0070","BK0239","300199"],"gpt_icon":0},{"id":"2586206136","title":"医药“一哥”高管，空降翰宇药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2586206136","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586206136?lang=zh_cn&edition=full","pubTime":"2025-11-28 14:45","pubTimestamp":1764312358,"startTime":"0","endTime":"0","summary":"事后，涉案原高管被判刑，公司计提相关费用，对利润产生显著冲击。一个偶然的契机，其发现国内多肽赛道有巨大成长空间，由此找到医药专家袁建成，共同组建翰宇药业的前身。2022年，袁建成挪用公司资金案彻底浮出水面，其本人于2024年被终审判刑。其中，司美格鲁肽因受技术保护期限，国产厂家仍未获批上市，但进度较快的华东医药早已摩拳擦掌等待专利“开闸”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1764293051486213495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","BK1161","09939","300199","BK0077","BK1574","BK1515","BK0070","159938","BK0188","BK0028"],"gpt_icon":0},{"id":"2584621379","title":"翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584621379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584621379?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:12","pubTimestamp":1763388778,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，翰宇药业报收于19.4元，较前一交易日下跌3.29%，最新总市值为171.35亿元。该股当日开盘19.81元，最高19.83元，最低19.4元，成交额达7.17亿元，换手率为4.93%。近日，翰宇药业发布公告称，公司将于2025年12月5日召开2025年第四次临时股东大会，会议由董事会召集，采取现场投票与网络投票相结合的方式进行。股权登记日为2025年11月28日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0028","300199","BK0239","BK0077"],"gpt_icon":0},{"id":"2583756063","title":"翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2583756063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583756063?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:48","pubTimestamp":1763038129,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业11月13日在投资者关系平台上答复投资者关心的问题。公司定增及三季度业绩暴雷，至始至终没有给投资者一个好的回答，顾左言右，草草敷衍，给股价造成严重影响，希望公司能正视问题，躬身自省，出台措施做好市值管理，维护投资者利益！公司一直专注于主营，聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块，不断提升自身生产经营能力，力争实现更好的盈利，为股东创造更多价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0077","BK0028","BK0070","BK0188","BK0239"],"gpt_icon":0},{"id":"2581091651","title":"翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091651?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:11","pubTimestamp":1762438279,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，翰宇药业报收于20.83元，较前一交易日下跌2.16%，最新总市值为183.98亿元。该股当日开盘21.0元，最高21.15元，最低20.8元，成交额达8.28亿元，换手率为5.32%。本次股东大会于2025年11月6日以现场和网络投票方式召开，审议通过了《关于向深圳市高新投集团有限公司及下设子公司融资的议案》。表决结果显示，同意股份占出席会议有效表决权的99.2557%，议案获得通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0028","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2579460101","title":"翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579460101","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579460101?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:48","pubTimestamp":1761864495,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2025年三季报。截至本报告期末，公司营业总收入6.83亿元，同比上升82.06%，归母净利润7135.15万元，同比上升305.0%。按单季度数据看，第三季度营业总收入1.34亿元，同比上升11.86%，第三季度归母净利润-7411.71万元，同比下降203.18%。本报告期翰宇药业短期债务压力上升，流动比率达0.37。本次财报公布的各项数据指标表现尚佳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2579144289","title":"翰宇药业：司美格鲁肽III期临床进入收尾阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144289","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144289?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:52","pubTimestamp":1761828735,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司计划何时公布司美格鲁肽三期临床测试结果？谢谢翰宇药业回复：公司司美格鲁肽注射液体重管理和和降糖适应症均已开展III期临床，所有受试者均已入组，已进行给药及随访，并进入收尾阶段，预计年内完临床试验，相关临床结果请关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0028","300199","BK0239","BK0077"],"gpt_icon":0},{"id":"2577879193","title":"翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577879193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577879193?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:10","pubTimestamp":1761055835,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，翰宇药业报收于21.45元，较前一交易日上涨0.99%，最新总市值为189.46亿元。该股当日开盘21.07元，最高21.6元，最低20.8元，成交额达8.97亿元，换手率为5.66%。近日，翰宇药业发布公告称，公司将于2025年11月6日15:30召开2025年第三次临时股东大会，会议将审议《关于向深圳市高新投集团有限公司及下设子公司融资的议案》。股东可于2025年11月3日前通过信函或传真方式登记，不接受电话登记。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100036871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0028","BK0077","BK0188","BK0239","BK0070"],"gpt_icon":0},{"id":"2570496072","title":"翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2570496072","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570496072?lang=zh_cn&edition=full","pubTime":"2025-09-26 15:07","pubTimestamp":1758870421,"startTime":"0","endTime":"0","summary":"中国经济网北京9月26日讯 翰宇药业 今日股价下跌，开盘报22.38元，跌幅3.20%。 翰宇药业昨晚披露的2025年度向特定对象发行A股股票预案显示，公司本次发行募集资金总额不超过人民币96,800.00万元(含本数)，在扣除相关发行费用后的募集资金净额将全部用于以下项目：多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、研发实验室升级项目、司美格鲁肽研发项目和补充流动资金。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202509/26/20250926886021.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202509/26/20250926886021.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20250926/31675299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300199","BK0028","BK0239","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"2570094527","title":"翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2570094527","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570094527?lang=zh_cn&edition=full","pubTime":"2025-09-25 19:40","pubTimestamp":1758800432,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，拟向特定对象发行股票，募集资金总额不超过9.68亿元，用于多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、研发实验室升级项目、司美格鲁肽研发项目及补充流动资金。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500030586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300199","BK0028","BK0077","BK0188"],"gpt_icon":0},{"id":"1125763108","title":"翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1125763108","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125763108?lang=zh_cn&edition=full","pubTime":"2025-09-25 19:35","pubTimestamp":1758800114,"startTime":"0","endTime":"0","summary":"翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","300199","BK0188","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2562426944","title":"股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562426944?lang=zh_cn&edition=full","pubTime":"2025-08-25 00:27","pubTimestamp":1756052834,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，翰宇药业报收于28.32元，下跌5.44%，换手率17.62%，成交量131.38万手，成交额37.35亿元。公司公告汇总：翰宇药业的醋酸阿托西班注射液获得越南药品上市许可，批件有效期至2030年7月17日。股本股东变化翰宇药业近日披露，截至2025年6月30日，公司股东户数为6.3万户，较3月31日增加5701户，增幅为9.95%。此外，翰宇药业还发布了2025年半年度非经营性资金占用及其他关联资金往来情况汇总表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500000377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","BK0077","300199","BK0070"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767248481951,"stockEarnings":[{"period":"1week","weight":-0.0433},{"period":"1month","weight":-0.0469},{"period":"3month","weight":-0.1608},{"period":"6month","weight":-0.0319},{"period":"1year","weight":0.3887},{"period":"ytd","weight":0.3887}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"110118人(较上一季度增加74.86%)","perCapita":"6771股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}